Loading
A phase 2 trial of Capmatinib, Gefitinib and Osimertinib in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone is a phase 2 interventional study registered as NCT03040973 by Novartis Pharmaceuticals, with 29 participants enrolled, started 2017-07-04 and due to reach its primary completion in 2027-07-30. Interventions recorded: Capmatinib, Nazartinib, Gefitinib and Osimertinib.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.